title: [Recombinant human erythropoietin (rh-EPO) in chronic, dialysis-dependent renal failure: effects on macro- and microcirculation and hematologic parameters].
abstract: Recombinant human erythropoietin (rh-EPO) has been shown to be effective in the treatment of renal anemia. Additionally, rh-EPO improves the hemostatic defect of uremia. On the other hand, a hypertensinogen effect and an increased risk for thrombosis have been reported in hemodialysis (HD) patients with rh-EPO. 20 HD patients in Homburg were recruited for a multicenter, placebo-controlled study (MF 3981), aiming to assess the risk of rh-EPO. Initially, 10 patients received rh-EPO at a dose of 3 x 80 U/kg body weight and week which was subsequently adjusted according to the hematocrit. After 6 months, the patients receiving placebo were changed to rh-EPO therapy. Clinical and laboratory data were obtained before, as well as 1, 3, 6 and 12 months after beginning of the study. Erythrocyte counts increased significantly in the rh-EPO group. Also, an increase of platelet count, fibrinogen and plasma viscosity was observed during rh-EPO. Tissue type plasminogen activator and plasminogen activator inhibitor as well as von-Willebrand-factor remained unchanged, although a shortening of the bleeding time was observed. Blood pressure and arterial blood flow were not influenced by rh-EPO.
authors.affiliation: Abteilung für klinische Hämostaseologie, Universität des Saarlandes, Homburg/Saar.
authors.forename: M
authors.initials: M
authors.lastname: Köhler
authors.forename: S
authors.initials: S
authors.lastname: Mörsdorf
authors.forename: F
authors.initials: F
authors.lastname: Jung
authors.forename: B
authors.initials: B
authors.lastname: Braun
authors.forename: P
authors.initials: P
authors.lastname: Waldhausen
authors.forename: G
authors.initials: G
authors.lastname: Pindur
authors.forename: U
authors.initials: U
authors.lastname: Weber
authors.forename: R
authors.initials: R
authors.lastname: Bosslet
authors.forename: R
authors.initials: R
authors.lastname: Bambauer
authors.forename: G A
authors.initials: GA
authors.lastname: Jutzler
mesh_terms: D001809:Blood Viscosity / Q000187:drug effects*; D004906:Erythrocyte Count / Q000187:drug effects*; D004921:Erythropoietin / Q000008:administration & dosage* / Q000009:adverse effects; D006400:Hematocrit; D006801:Humans; D006977:Hypertension, Renal / Q000097:blood; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage; D006435:Renal Dialysis; D012307:Risk Factors; D013927:Thrombosis / Q000097:blood
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin
vernacular_title: Rekombinates humanes Erythropoietin (rh-EPO) bei chronischer, dialysepflichtiger Niereninsuffizienz: Auswirkungen auf die Makro- und Mikrozirkulation und hämatologische Parameter.